| 000 | 01491 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250515092909.0 | ||
| 264 | 0 | _c20071113 | |
| 008 | 200711s 0 0 eng d | ||
| 022 | _a0250-7005 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPande, Amitkumar | |
| 245 | 0 | 0 |
_aHypertension secondary to anti-angiogenic therapy: experience with bevacizumab. _h[electronic resource] |
| 260 |
_bAnticancer research _c |
||
| 300 |
_a3465-70 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension _xchemically induced |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeovascularization, Pathologic _xdrug therapy |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aUnited States _xepidemiology |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor A _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor Receptor-1 _xmetabolism |
| 650 | 0 | 4 |
_aVascular Endothelial Growth Factor Receptor-2 _xmetabolism |
| 700 | 1 | _aLombardo, Jeffrey | |
| 700 | 1 | _aSpangenthal, Edward | |
| 700 | 1 | _aJavle, Milind | |
| 773 | 0 |
_tAnticancer research _gvol. 27 _gno. 5B _gp. 3465-70 |
|
| 999 |
_c17491097 _d17491097 |
||